Sun Pharma gets CDSCO Panel nod to study Tildrakuzimab

Published On 2022-12-23 12:30 GMT | Update On 2022-12-23 12:30 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has given its nod to study the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active psoriatic arthritis II.

This came after the drug major Sun Pharma presented justification along with the Phase III clinical trial of the monoclonal antibody Tildrakuzimab protocol no. TILD19-19 amendment 1.1 (India Specific) dated 04/07/2022 (Inspire 2) before the committee.

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease which develops in patients with psoriasis. It is characteristic that the rheumatoid factor in serum is absent. Etiology of the disease is still unclear but a number of genetic associations have been identified.

Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.

Tildrakuzimab is a targeted immunomodulator that decreases inflammation by inhibiting the action of various cytokines associated with plaque psoriasis, thus relieving its symptom of scaly plaques

At the recent SEC meeting for Analgesic & Rheumatology held on 14th December 2022, the expert panel reviewed the justification and the Phase III clinical trial of the monoclonal antibody protocol no. TILD19-19 amendment 1.1 (India Specific) dated 04/07/2022 (Inspire 2).

The committee noted that as per the proposed protocol, Methotrexate/Leflunomide /SoC is already mentioned in the protocol and is to be provided in the placebo arm as well as the treatment arm throughout the treatment during the conduct of the trial.

Furthermore, the expert panel noted that the drug major Sun Pharma agreed that the Data and Safety Monitoring Board (DSMB) recommendation to be submitted to CDSCO and more Govt. sites to be included in the study.

After detailed deliberation, the committee recommended the grant of permission to conduct the study of the monoclonal antibody Tildrakuzimab.

Also Read:Conduct CT in Indian population: CDSCO Panel Tells AstraZeneca for Anifrolumab

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma gets CDSCO Panel nod to study Tildrakuzimab

Similar News

Pharma Firm, Director Under ED Lens Over Alleged Rs 60 Crore PNB Fraud

NPPA Expert Committee Recommends Pricing for Abbott's Clarithromycin Tablet, Cautions Firm Over Form Error

CDSCO Launches One-Year Online Dual Use NOC System for Bulk Drug Imports

Thermo Fisher gets USFDA nod for NGS-based Companion Diagnostic for new Non Small Cell Lung Cancer treatment

Emcure Pharma Gets CDSCO Panel Nod for Phase III Trial of Semaglutide in Chronic Weight Management

Zepto makes pharma foray: Medicines at your doorstep in 10 minutes

Healthium Medtech appoints Vinod T Varghese as Group Chief Human Resources Officer

Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban